Safety of Anti-Reelin Therapeutic Approaches for Chronic Inflammatory Diseases

Calvier L, Alexander A, Marckx AT, Kounnas MZ, Durakoglugil M, Herz J 2024 Apr 13

Reelin through the years: From brain development to inflammation

Alexander A, Herz J, Calvier L 2023 Jun 42

Circulating Reelin promotes inflammation and modulates disease activity in acute and long COVID-19 cases

Calvier L, Drelich A, Hsu J, Tseng CT, Mina Y, Nath A, Kounnas MZ, Herz J 2023 14

The “6B” Strategy: Build Back a Better Blood–Brain Barrier

Calvier L, Alexander AE, Herz J 2022 Sep 2 506-511

Editorial: New Advances in Cardiorenal Syndrome

Calvier L, Kökény G, Martinez-Martinez E 2022 Jul 9

Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmonary Hypertension

Calvier L, Herz J, Hansmann G 2022 Feb 7 164-180

PPARγ and TGFβ—Major regulators of metabolism, inflammation, and fibrosis in the lungs and kidneys

Kökény G, Calvier L, Hansmann G 2021 Oct 22

Reelin changes hippocampal learning in aging and Alzheimer's disease

Marckx AT, Fritschle KE, Calvier L, Herz J 2021 Sep 414

Apolipoprotein E receptor 2 deficiency decreases endothelial adhesion of monocytes and protects against autoimmune encephalomyelitis

Calvier L, Manouchehri N, Sacharidou A, Mineo C, Shaul PW, Hui DY, Kounnas MZ, Stüve O, Herz J 2021 Aug 6

CD11c+CD88+CD317+ myeloid cells are critical mediators of persistent CNS autoimmunity

Manouchehri N, Hussain RZ, Cravens PD, Esaulova E, Artyomov MN, Edelson BT, Wu GF, Cross AH, Doelger R, Loof N, Eagar TN, Forsthuber TG, Calvier L, Herz J, Stüve O 2021 Apr 118

Reelin Depletion Protects Against Atherosclerosis by Decreasing Vascular Adhesion of Leukocytes

Calvier L, Xian X, Lee RG, Sacharidou A, Mineo C, Shaul PW, Kounnas MZ, Tsai S, Herz J 2021 Apr 41 1309-1318

Reelin depletion protects against autoimmune encephalomyelitis by decreasing vascular adhesion of leukocytes

Calvier L, Demuth G, Manouchehri N, Wong C, Sacharidou A, Mineo C, Shaul PW, Monson NL, Kounnas MZ, Stüve O, Herz J 2020 Aug 12

PPARγ is a gatekeeper for extracellular matrix and vascular cell homeostasis: Beneficial role in pulmonary hypertension and renal/cardiac/pulmonary fibrosis

Kökény G, Calvier L, Legchenko E, Chouvarine P, Mózes MM, Hansmann G 2020 Mar 29 171-179

Activation of the metabolic master regulator PPARg: A potential pioneering therapy for pulmonary arterial hypertension

Hansmann G, Calvier L, Risbano MG, Chan SY 2020 62 143-156

The PPARγagonist pioglitazone prevents TGF-β induced renal fibrosis by repressing EGR-1 and STAT3

Németh Á, Mózes MM, Calvier L, Hansmann G, Kökény G 2019 Jul 20

LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPARγ Activation

Calvier L, Boucher P, Herz J, Hansmann G 2019 Jun 124 1778-1785

Chronic TGF-b1 signaling in pulmonary arterial hypertension induces sustained canonical Smad3 pathways in vascular smooth muscle cells

Calvier L, Chouvarine P, Legchenko E, Kokeny G, Mozes MM, Hansmann G 2019 61 121-123

Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats

Martínez-Martínez E, Ibarrola J, Fernández-Celis A, Calvier L, Leroy C, Cachofeiro V, Rossignol P, López-Andrés N 2018 Feb 36 368-376

Transforming growth factor β1-and bone morphogenetic protein 2/PPARγ-regulated MicroRNAs in pulmonary arterial hypertension

Calvier L, Chouvarine P, Legchenko E, Hansmann G 2017 Nov 196 1227-1228

PPARγ Links BMP2 and TGFβ1 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism

Calvier L, Chouvarine P, Legchenko E, Hoffmann N, Geldner J, Borchert P, Jonigk D, Mozes MM, Hansmann G 2017 May 25 1118-1134.e7

Galectin-3 blockade reduces renal fibrosis in two normotensive experimental models of renal damage

Martinez-Martinez E, Ibarrola J, Calvier L, Fernandez-Celis A, Leroy C, Cachofeiro V, Rossignol P, Lopez-Andres N 2016 Nov 11

Galectin-3 inhibition prevents adipose tissue remodelling in obesity

Martínez-Martínez E, Calvier L, Rossignol P, Rousseau E, Fernández-Celis A, Jurado-López R, Laville M, Cachofeiro V, López-Andrés N 2016 Jun 40 1034-1038

Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension

Calvier L, Legchenko E, Grimm L, Sallmon H, Hatch A, Plouffe BD, Schroeder C, Bauersachs J, Murthy SK, Hansmann G 2016 Mar 102 390-396

Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension

Martínez-Martínez E, Calvier L, Fernández-Celis A, Rousseau E, Jurado-López R, Rossoni LV, Jaisser F, Zannad F, Rossignol P, Cachofeiro V, López-Andrés N 2015 Oct 66 767-775

Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation

Martínez-Martínez E, Cachofeiro V, Rousseau E, Álvarez V, Calvier L, Fernández-Celis A, Leroy C, Miana M, Jurado-López R, Briones AM, Jaisser F, Zannad F, Rossignol P, López-Andrés N 2015 Aug 411 20-27

The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries

Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, Zannad F, Rossignol P, López-Andrés N 2015 Jan 3 59-67

Galectin-3 mediates aldosterone-induced vascular fibrosis

Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, De Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N 2013 Jan 33 67-75

Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice

López-Andrés N, Calvier L, Labat C, Fay R, Díez J, Benetos A, Zannad F, Lacolley P, Rossignol P 2013 Jan 61 120-129

Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction

López-Andrés N, Rousseau A, Akhtar R, Calvier L, Iñigo C, Labat C, Zhao X, Cruickshank K, Díez J, Zannad F, Lacolley P, Rossignol P 2012 Aug 60 563-573